BioMark Diagnostics Inc.
BUX
CNSX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -1.09% | -2.14% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -1.09% | -2.14% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -1.09% | -2.14% | |||
| SG&A Expenses | 61.30% | -49.54% | |||
| Depreciation & Amortization | 278.23% | -1.88% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 87.08% | -46.64% | |||
| Operating Income | -98.58% | 49.63% | |||
| Income Before Tax | -22.91% | 40.39% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -22.91% | 40.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -22.91% | 40.39% | |||
| EBIT | -98.58% | 49.63% | |||
| EBITDA | -100.19% | 50.01% | |||
| EPS Basic | -833.33% | 93.18% | |||
| Normalized Basic EPS | -750.00% | 92.86% | |||
| EPS Diluted | -833.33% | 93.18% | |||
| Normalized Diluted EPS | -750.00% | 92.86% | |||
| Average Basic Shares Outstanding | -88.13% | 874.01% | |||
| Average Diluted Shares Outstanding | -88.13% | 874.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||